Avalon reports successful completion of phase i study of car t-cell therapy candidate

Avalon globocare announces successful completion of phase i clinical study of car t-cell therapy candidate ava-001.avalon globocare corp - treatment with ava-001 was generally well tolerated with minimal toxicities and adverse side effects.avalon globocare corp - will present results of this ava-001 phase 1 clinical trial on july 11,2020.
AVCO Ratings Summary
AVCO Quant Ranking